Prakt. lékáren. 2011; 7(3): 121-125

New medicinal substances in extemporaneous prescription, part 9 - fluocinolone acetonide

PharmDr.Zbyněk Sklenář, Ph.D.1,2, Mgr.Kateřina Horáčková2
1 Vyšší odborná škola zdravotnická, Plzeň
2 Lékárna Na Rohožníku, Praha

The range of corticosteroids available for the extemporaneous preparation in pharmacies has expanded because fluocinolone acetonide,

a double-fluorinated corticosteroid, has been available as a pharmaceutical substance since mid-December 2010. The article provides

information on the properties and use of this substance and shows the options of incorporation into topical semi-solid and liquid pharmaceutical

preparations. Also presented are examples of formulas suitable for magistral preparations, thus it will no longer be necessary to

mix proprietary medicinal products containing fluocinolone acetonide in extemporaneous preparations.

Keywords: fluocinolone acetonide, corticosteroids, magistral preparation, fluocinolone acetonide solubility

Published: June 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sklenář Z, Horáčková K. New medicinal substances in extemporaneous prescription, part 9 - fluocinolone acetonide. Praktické lékárenství. 2011;7(3):121-125.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Borovanský A, Csöllei J. Farmaceutická chemie (Farmakochemie) VII. Léčiva s účinkem na endokrinní systém (hormony). 1. vyd. Brno: VFU Brno, 2007: 177 s.
    2. Gloor M, Thoma K, Fluhr J. Dermatologische Externatherapie unter besonderer Berücksichtigung der Magistralrezeptur. Berlin, Heidelberg: Springer-Verlag, 2000: 469 s. Go to original source...
    3. Fadrhoncová A. Farmakoterapie kožních nemocí. 2., přeprac. a rozšíř. vyd. Praha: Grada Publishing s.r.o., 1999: 415 s.
    4. Viktorinová M. Přehled lokálních kortikosteroidů v dermatologii 1. Možnosti léčby kožních chorob kortikosteroidními externy. Klin Farmakol Farm 2006; 20(4): 202-210.
    5. Kolektiv autorů. Remedia Compendium. 4., přeprac. a rozšíř. vyd. Praha: Panax Co, s. r. o, 2009: 946 s.
    6. Mikro-verze AISLP - Automatizovaný informační systém léčivých přípravků. [CD-ROM]. Ver. ČR 2011.1 pro MS Windows platná k 1. 1. 2011. Praha, 2011.
    7. Wynn RL, Meiller TF, Crossley HL. Drug information handbook for dentistry. 15th ed. Ohio: Lexi-Comp, 2009: 2223 p.
    8. Buajeeb W, Pobrurksa C, Kraivaphan P. Efficacy of fluocinolone acetonide gel in the treatment of oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89(1): 42-45. Go to original source... Go to PubMed...
    9. http://www.bausch.com/en_US/ecp/general/product/ecp_retisert.aspx (datum náhledu: 10. 3. 2011).
    10. http://www.hillderm.com/prescribing-information/dermotic-oil.shtml (datum náhledu: 10. 3. 2011).
    11. Bartolomei M, Ramusino MC, Ghetti P. Solid-state investigation of fluocinolone acetonide. J Pharm Biomed Anal 1997; 15(12): 1813-1820. Go to original source... Go to PubMed...
    12. Brode E. Untersuchungen zur Stabilität von Fluocinolonacetonid in pharmazeutischen Zubereitungen. Arzneimittelforschung 1967; 17(1): 103-108.
    13. Comer JP, Hartsaw PE. Thin-layer chromatographic stability assay for C14-labeled steroid in a cream. J Pharm Sci 1965; 54(4): 524-527. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.